冠心病秽浊痰阻证与血管内皮损伤的关系研究
|
摘要
目的:通过对血浆内皮素(ET)、血浆血栓调节蛋白(TM)的含量变化观察,初步探讨冠心病秽浊痰阻证与血管内皮损伤之间的关系,进一步为制定冠心病秽浊痰阻证的诊断标准提供微观的客观依据,使冠心病秽浊痰阻证的诊断趋于客观化。方法:选取冠心病秽浊痰阻证84例、冠心病非秽浊痰阻证88例、健康对照组78例;观察三组一般资料及血浆内皮素(ET)、血浆血栓调节蛋白(TM)的含量的变化。结果:1)血浆ET含量的比较:与健康对照组相比,冠心病秽浊痰阻证组、非秽浊痰阻证组患者血浆ET含量均明显增高,差异有统计学意义(P<0.01);冠心病秽浊痰阻证组血浆ET含量与非秽浊痰阻证组比较,差异亦有统计学意义(P<0.05);2)血浆TM含量的比较:与健康对照组相比,冠心病秽浊痰阻证组、非秽浊痰阻证组患者血浆TM含量增高,差异均有统计学意义(P<0.01);冠心病秽浊痰阻证组血浆TM含量高于非秽浊痰阻证组(P<0.05)。结论:冠心病秽浊痰阻证的实质是秽浊痰湿阻于脉道,闭阻气血,而致痰瘀内生,微观表现是ET、TM水平升高,表明冠心病秽浊痰阻证与非秽浊痰阻证相比,其血管内皮损伤更为明显。血浆ET、TM可以作为冠心病秽浊痰阻证中医辨证的客观依据。
Objective:The aim of this study is to investigate the plasma level of Endothelin(ET) and Thrombomodulin(TM), so as to explore the relationship between CHD HuiZhuoT- anzhu Syndrome and endothelium dysfunction, provide the microcosmic objective basis for working out the diagnose standard for the coronary heart disease HuiZhuoTanZu Syndrome, in order to make its diagnose tend being externalization. Methods: A total of 172 samples were obtained from 84 cases of CHD huizhuotanzu syndrome and 88 cases of CHD non-huizhuotanzu syndrome, 78 cases of normal controls, then observe and analyses the general data and the plasma level of ET、TM among three groups. Results: 1) Comparison of plasma ET: Compared with normal controls, the lever of ET of CHD HuiZhuoTanzhu Syndrome group and non-HuiZhuoTanzhu Syndrome group are significantly higher, the difference is statistically significant (P<0.01 ); between CHD HuiZhuoTanzhu Syndrome group and the non- HuiZhuoTanzhu Syndrome group, there is a significant difference in the lever of ET (P<0.05). 2) Plasma TM level in comparison: the lever of TM in CHD HuiZhuoTanzhu Syndrome group and non- HuiZhuoTanzhu Syndrome group are higher than healthy control group, the difference is significant (P<0.01), and the lever of TM in CHD HuiZhuoTanzhu Syndrome group is higher than non-HuiZhuoTanzhu Syndrome group (P<0.05). Conclusion:The essence of CHD HuiZhuoTanZu syndrome is huizhuo resistance in the veins Road, closed resistance blood,result in phlegm and blood stagnate in the body, the microcosmic performance is that the levers of ET and TM has increased, there are obvious endothelium dysfunction state in the CHD HuiZhuoTanZu syndrome than non-HuiZhuoTanZu syndrome.The increasing contents of ET、TM can help us to differentiate the CHD HuiZhuoTanZu syndr- omee and non-HuiZhuoTanZu syndrome.
Objective:The aim of this study is to investigate the plasma level of Endothelin(ET) and Thrombomodulin(TM), so as to explore the relationship between CHD HuiZhuoT- anzhu Syndrome and endothelium dysfunction, provide the microcosmic objective basis for working out the diagnose standard for the coronary heart disease HuiZhuoTanZu Syndrome, in order to make its diagnose tend being externalization. Methods: A total of 172 samples were obtained from 84 cases of CHD huizhuotanzu syndrome and 88 cases of CHD non-huizhuotanzu syndrome, 78 cases of normal controls, then observe and analyses the general data and the plasma level of ET、TM among three groups. Results: 1) Comparison of plasma ET: Compared with normal controls, the lever of ET of CHD HuiZhuoTanzhu Syndrome group and non-HuiZhuoTanzhu Syndrome group are significantly higher, the difference is statistically significant (P<0.01 ); between CHD HuiZhuoTanzhu Syndrome group and the non- HuiZhuoTanzhu Syndrome group, there is a significant difference in the lever of ET (P<0.05). 2) Plasma TM level in comparison: the lever of TM in CHD HuiZhuoTanzhu Syndrome group and non- HuiZhuoTanzhu Syndrome group are higher than healthy control group, the difference is significant (P<0.01), and the lever of TM in CHD HuiZhuoTanzhu Syndrome group is higher than non-HuiZhuoTanzhu Syndrome group (P<0.05). Conclusion:The essence of CHD HuiZhuoTanZu syndrome is huizhuo resistance in the veins Road, closed resistance blood,result in phlegm and blood stagnate in the body, the microcosmic performance is that the levers of ET and TM has increased, there are obvious endothelium dysfunction state in the CHD HuiZhuoTanZu syndrome than non-HuiZhuoTanZu syndrome.The increasing contents of ET、TM can help us to differentiate the CHD HuiZhuoTanZu syndr- omee and non-HuiZhuoTanZu syndrome.
引文
[1]孔灵芝.慢性非传染性疾病流行现状,发展趋势及防治策略.中国慢性病预防与控制[J]2002, 10(1):1.
[2]杨功焕.健康模式转变与中国慢性病控制策略.中国慢性病预防与控制[J],2001, 9(4)145.
[3] Jean-Pierre Bassand.氯吡格雷治疗急性冠状动脉综合症:新证据和用药原则[S].中国医学论坛报, 2005, 6(30):18-19.
[4]吴海磊,张金良.气温及太阳活动变化对疾病发生的研究进展[J].卫生研究,2004,33(5):641-643.
[5]郭蕾,乔之龙.论开展六淫现代研究的重要意义[J].辽宁中医杂志,2004,31(7): 548-549.
[6]王锡稳,王宝鉴,黄玉霞,等.兰州市心血管病与气象条件分析[J].甘肃气象,2001, 19(1):29-32.
[7]李健,丁邦晗,张敏州等.胸痹心痛的临床证型与部分冠心病危险因素的对比研究[J].中西医结合心脑血管病杂志,2005,3(2):97-99.
[8]解玉水,吴士尧,王芝兰等.沪、疆两地急性心肌梗死的对比分析[J].中国综合临床,2005,21(9):786-788.
[9]成孚民,沈宝藩.成孚民医案医话集[M],新疆人民出版社,1985.
[10]安冬青,胡金霞,赵明芬,等.天香丹对冠心病病人血管内皮生长因子及相关因子的影响[J].中西医结合心脑血管病杂志,2007,5(8):662～664.
[11]安冬青,胡金霞,郑静,等.天香丹对冠心病患者血管新生相关因子的影响[J].新疆医科大学学报,2007,30(5):437～439.
[12]安冬青,施建民,姚海洪.天香丹对冠心病血管调节肽、血栓素A2/前列环素影响的临床与实验研究[J].心功能杂志,1998,10(2):118.
[13]安冬青.天香丹对冠心病患者血浆内皮素、降钙素基因相关肽的影响.中国医学文摘内科学分册英文版,1999,16(6):44.
[14]张玲,安冬青.天香丹颗粒对不稳定性心绞痛的相关炎性因子的影响[J].新疆中医药,2005,23(3):22～23.
[15]殷建明,朱江丽,刘琴,等.天香丹颗粒对冠心病心绞痛患者血清中T-SOD、GSH-Px、MDA、LD的影响[J].中国中医药信息杂志,2003,10(7):13～15.
[16]Michael A. Vascular endothelium:An integrator of pathophysio-logic stimuli theroscerosis[J]. Am J Cardiol,1995, 75:67B.
[17]潘雪峰,董华进,宫泽辉.内皮素与心血管功能研究的最新进展.国外医学(药学分册) ,2007,(01) :12-16.
[18]Conway EM,Van de Wouwer M,Pollefeyt S,et al.The lectin-like domain of thrombomodulin confers by suppressing adhesion activated protein kinase pathways.J ExPMed, 2002, 196 (5):565-577.
[19]LiYH,Chen JH,WuHL.et al.G-33A mutation in the promoter region of thrombomodulin geneand its assoeiation with coronary artery disease and plasma soluble thrombomodulin levels.AnlJCardio,2000,85(1):8-12.
[20]周仲英.中医内科学[M].第二版.北京中国中医药出版社. 2007,135-144.
[21]杨树勤.卫生统计学[M].第三版.北京:人民卫生出版社.1992.146.
[22]胡冬裴,胸痹证治文献研究[J],山东中医药大学学报,2005,9(1):38-40.
[23]梁达樵.辨证求真[M].广州十八甫维新印务局:光绪乙已,18-19.
[24]陈其昌.湿证发微[M].河南商务印刷所,民国十二年,25-30.
[25]殷建明,安冬青,通补开泄法治疗冠心病理论探讨[J].中医研究,2003,16(4):6-8.
[26]安冬青.天香丹耐缺氧及抗心肌缺血作用的试验研究[J].中国老医学杂志,2002,22: 47-48.
[27]张焱,安冬青.天香丹治气虚血瘀冠心病临床观察[J].江西中医药,2002,33(3):6-7.
[28]殷建明,朱江丽,安冬青.天香丹颗粒对冠心病心绞痛患者血清中T-SOD、GSH-PX、MDA、LD的影响[J].中国中医药信息杂志,2003,10(7):13-15.
[29]李必旭,安冬青,张焱.天香丹对冠脉结扎大鼠血浆NO、ET的影响[J].中医药研究,2002,18(1):41-42.
[30]安冬青,施建民,姚海洪.天香丹对冠心病血管调节肽、血栓素A2/前列环素影响的临床与实验研究[J].心功能杂志,1998,10(2):118.
[31]安冬青.天香丹对冠心病患者血浆内皮素、降钙素基因相关肽的影响[J].中国医学文摘内科学分册英文版,1999,16(3):44.
[32]杨建梅,安冬青.ICAM-1、VCAM-1与冠心病研究进展[J].新疆医学,2002,32(5):81.
[33]施建明,安冬青,张晓天等.天香丹治疗脂质代谢紊乱的临床研究[J].中国中医药信息杂志,1999,6(11):38-39.
[34]张玲,安冬青.天香丹颗粒对不稳定性心绞痛的相关炎性因子的影响[J].新疆中医药,2005,23(3):22-24.
[35]加力肯,安冬青.天香丹对冠心病稳定型心绞痛患者生活质量的影响及疗效分析[J].新疆医科大学学报,2006,29(11):1053-1055.
[36]Brown R E,Nahser P J, Rossen J D, et a.l Vasoconstriction of coro nary stenses from exposure to envionmental tobacoo smoke(abstract) [J]. JAm CollCardio,l 1994,(Suppl): 107A.
[37]KlasM, PeterB,Ander H. Clinical and biochemical factors associ ated with prognosis after myocardical infarction at a young age[J]. JAm CollCardiol,1994, 24: 59.
[38]周铭心.西北燥证研究概述[J].上海中医药杂志,2005,39(11):43-44.
[39]周铭心,凌泽奎.燥邪属性辨析—西北燥证病因学研究[J].新疆中医药.2005,23(6): 1-3.
[40]李超,安冬青,王娟,等.冠心病秽浊痰阻证与血浆同型半胱氨酸的相关性研究[J].中西医结合心脑血管病杂志,2008,6(4):384～385.
[41]孙红艳,安冬青,宋刚.冠心病秽浊痰阻证与血浆t-PA、PAI-1及Fib的相关性研究[J].中西医结合心脑血管病杂志,2009,7(4):389～390.
[42]王娟,安冬青,申艳慧,等.冠心病秽浊痰阻证与纤维蛋白原的关系探讨[J].中西医结合心脑血管病杂志,2008,6(4):383.
[43]王云龙,安冬青,朱萌,等.冠心病秽浊痰阻证与血管血友病因子的相关性研究[J].中西医结合心脑血管病杂志, 009,7(4):393～394.
[44]Rubanyi GM. The role of endothelium in cardiovascular homeostasis and diseases [J]. J Cardiovasc Pharmacol,1993, 22(Suppl 4): S1-S14.
[45]Paterick TE, Fletcher GF. Endothelial function and cardio-vascular prevention: role of blood lipids, exercise, and other risk factors[J]. Cardiol Rev, 2001, 9(5): 282-286.
[46]边东哲.动脉粥样硬化、冠心病与血管内皮细胞损伤机制的研究概况[J].湖南中医药导报,2003,(06) :63-65.
[47]Boehme M W, Raeth U, Scherbaum W A, et al. Interaction of endothelial cells and neutrophils in vitro: kinetics of thrombomodulin, intercellular adhesion molecule-1 (ICAM-1), E-selectin, and vascular celadhesion molecule-1 (VCAM-1): implications for the relevance as serological disease activity markers in vasculitides[J].Clin Exp Immunol,2000, 119:250.
[48]廖新学,李欣,马虹,等.冠心病患者血浆血栓调节蛋白水平的测定及其临床意义中国心血管杂志2003,8,(2)103-104.
[49]Lusis AJ.Atherosclerosis[J].Nature,2000,407(6 801):233-241.
[50]俞梦越,吴维力.内皮功能不全与冠心病[J].心血管病学进展,2002, (4):193-199.
[51]齐法莲,许军.内皮素研究与血管疾病[J].放射免疫学杂志,2002,15(4):246.
[52]Masaki T,Ninomiy H,Sakamoto A,et al.Structural basis of the function of endothelin eceptor[J].Mol Cell Biochem,1999,190:153-158.
[53]詹萍,熊尚全,郭跃进,等.不稳定性心绞痛不同中医证型与内皮素和心钠素关系[J].中西医结合心脑血管病杂志,2007,5(10):936-937.
[54]ZuK-Popiolek L,Flak Z,FrancuzT,et al.Plasma endothelin-1inpatients with stable or unstableangina[J].Kardiol Pol,2003,58(6):429-437.
[55]Herrmann J,Best PJ,Ritman EL,et al.Chronic endothelin receptor antagonism prevents coronary vasa vasorum neovascular-ization in experimental hypercholesterolemia [J]. J Ma Coll Cardiol,2002,39 (9):1555.
[56]李福刚,吾柏铭.冠心病患者血小板活化状态的观察[J].中华内科杂志,1993,32(1): 17-18.
[57]卢建敏,王丽霞,高思民.不稳定性心绞痛病人血浆内皮素的改变及低分子量肝素对它的影响[J].国外医学:心血管疾病分册,2000,27(2):100.
[58]郑春霞,刘志霞.血管内皮细胞损伤及其检测[J].肾脏病与透析肾移植杂志,2007,16 (1):64-65.
[59] Mombouli JV, Vanhoutte PM. Endothelial dysfunction:from physiology to therapy[J]. J Mol Cell Cardiol, 1999,31(1): 61-74.
[60]Kinlay S, Libby P, Ganz P. Endothelial function and coronary artery disease[J]. Curr Opi Lipidol, 2001,12 (4): 383-389.
[61]Farquharson CA,Butler R,Hill A,Belch JJ,StruthersAD.Allopurin improves endothelial dysfunction in chronic heart failure[J]. Circulation 2002,106(2):221.
[62]Hoeg JM. Expanding and understanding risk factors for coronary headisease[J]. JAMA, 1997,277(17):1387.
[63]中华医学会心血管病学分会中华心血管病杂志编辑委员会,第二届全国血脂异常学术研讨会会议纪要.中华心血管病杂志,2002,30:64 3-646.
[64]Gordon T, Kannel WB, Castelli WP, et al. Lipoproteins,cardiovascular disease,and death.The Framingham study. Arch Intern Med, 1981,141:1128-1131.
[65]冯宁.小、密低密度脂蛋白与冠心病[J].中华心血管病杂志,1997,25:237.
[66]Grundy SM.RoIe of low-density lipoproteins in atherogenesis and development of coronary heart disease. Clin Chem.1995 Jan;41(1):139-146.
[67]Rubins HB,Rubins SJ,Collins D,et al. Distribution of lidpids in 8500 men with coronary artery disease[J]. Am J Cardiol,1995,75:1196-1201
[68]Castelli WP,Garrision RJ,Wilson PW,et al. Incidence of coronary artery disease and lipoprotein cholesterol levels[J]. The Framing-ham study.JAMA,1986,256:2835-2838
[69]Stampter MJ,Krauss RM,Ma J, et a1.Aprospectiue study of triglyceride level,low-density lipoprotein particle diameter and risk of myocardial infraction.JAMA, l 996,276:882.
[70]韩学杰,沈绍功.中医治疗冠心病心绞痛研究进展[J].中国中医基础医学杂志,2003, 9(2):78-80.
[71]陈冰,宋剑南,牛小红,等.健脾祛痰化瘀方对氧化型低密度脂蛋白诱导血管细胞信号分子钙离子和蛋白激酶c表达的影响[J].中国动脉硬化杂志,2004,12(2):143-145.
[72]陈皋,宋剑南,史国锋,等.沥水调脂胶囊在体外对弱氧化型低密度脂蛋白诱导血管平滑肌细胞增殖的影响[J].中国中医基础医学杂志,2003,9(4):52-55.
[73]陈忠,黄峻.载脂蛋白E与动脉粥样硬化及早发冠心病[J].医学综述,2002,8(4):215- 216.
[74]蔡师敏,黄发盛.冠心病中医辨证分型与血脂关系分析[J].福建中医药,1993,30(6): 12.
[75]王剑,严灿,邓中炎,等.从粘附分子代谢失常探讨痰证机理[[J].中国中西医结合杂志,2000,20(4):296.
[76]张丽芬,李秀满.中医痰证的现代研究[J].天津中医学院学报,2000,12(3):17-19.
[77]宋剑南.中医药防治动脉粥样硬化研究进展[J].中国中医基础医学杂志,2003,9(11): 71-74.
[78]韩学杰.沈绍功教授从痰论治冠心病经验[J].中国中医急症,2004,13(1):31～32.
[79]谢海波,陈新宇,石刚,等.冠心病心绞痛中医证型与C-反应蛋白、血脂的相关性研究[J].湖南中医药大学学报,2005,25(4):32-34.
[80]于顾然,贺燕群,郭云庚,等.冠心病中医证型与胰岛素抵抗、脂质及红细胞膜酶关系的临床研究[J].中医杂志,2004,41(2):111-112.
[81]刘文波,殷少华,孙小键,等.冠心病患者血清尿酸和胆红素水平的变化[J].中华心血管病杂志, 2003, 31, (6): 439.
[82]Puddu PE,Lanti M,Menotti A,et al.Serum uric for short-term prediction of cardiovascular disease incidence in the Gubbio popu-lation study[J].Acta Cardiol,2001,56(4):243-251.
[83]Freedam DS,Williamson DF,Gunter EW,et al.Relation of serum uric acid to mortality and ischemic heart disease[J]. Am J Epidemiol, 1995, 141 (7):637-644.
[84]SattarN,Petrie JR,JaapAJ,et al.The atherogenic lipoprotein phenol type and vascular endothelial dysfunction[J].Atherosclerosis,1998,138:229-235.
[85]CerielloA.TabogaC.Tonutti L.Evidence for an independent and cumulative effect of postprandial hypertriglyceridemia and hyperglycemia on endothelial dysfunction and oxidative stressgeneration:effects of short and long-term simvastatin treatment[J]. Circulation,2002,106(10):1211-1218.
[86]Ward HJ.Uric acid as independent risk factor in the treat-ment of hypertension [J].Lancet,1998,352:670-671.
[87]Kanellis J,Watanabe S,Li JH,et al.Uric acid stimulates monocyte chemoattractant protein-1 production in vascular smooth muscle cells via mitogen-activated protein kinase and cyclooxygenase-2. Hypertension,2003,41:1287-1293.
[1]丁书文,李晓.冠心病内皮损伤防治研究进展[J].菏泽医专学报,2000,12,(3)180-182.
[2]边东哲.动脉粥样硬化、冠心病与血管内皮细胞损伤机制的研究概况[J].湖南中医药导报,2003,(06) .63-65.
[3]刘国英,陈还珍,吴博威.改善血管内皮功能防治冠心病研究进展[J].心血管病学进展,2006,27:39-41.
[4] Puranik R,Celermajer DS.Smoking and endothelial function[J].Prog Cardiovasc Dis,2003,45(6):443-584.
[5] Ali-Raza J,Movahed A.Current concepts of cardiovascular diseases in diabetes mellitus[J].Int J Cardiol,2003,89(2-3):123-134.
[6] Woodman CR,Price EM,Laughlin MH.Selected contribution:aging impairs nitric oxide and prostacyclin-mediation of endothelium-dependent dilation in soleus feed arteries[J].J Appl Physiol,2003,95(5):2164-2170.
[7] Shah SV,Alam MG.Role of iron in atherosclerosis[J].Am J Kidney Dis,2003,41(3 suppl 1):S80-S83.
[8] Nedeljkovic ZS,Gokce N,Loscalzo J.Mechanisms of oxidativestress and vascular dysfunction[J].Postgrad Med J,2003,79:195-200.
[9]廖新学,李欣,马虹,等.冠心病患者血浆血栓调节蛋白水平的测定及其临床意义[J]中国心血管杂志,2003,8 (2):103-104.
[10]Lusis AJ.Atherosclerosis[J].Nature,2000,407(6 801):233-241.
[11]俞梦越,吴维力.内皮功能不全与冠心病[J].心血管病学进展, 2002, (04):193-199.
[12]Vanhoutte PM.Endothelial dysfunction and atherosclerosis[J].Eur heart J,1997,18(suppl):19-29.
[13]Makin AJ,Blann AD,ChungNA,et al.Assessment of endothelial damage in atheroscler- otic vascular disease by quantification of circulatingendothelial cells.Relationship with von Willebrand factor and tissuefactor[J].Eur Heart J,2004,25(5):371-376.
[14]Tio RA,Monnink SH,Amoroso G,et al.Safety evaluation of routine in-tracoronary acetylcholine infusion in patients undergoing a first diagnos-tic coronary angiogram[J].J InvestigMed,2002,50(2):133-139.
[15]Celermajer DS, Sorensen KE, Gooch VM, et al. Non-invasive detection of endothelial dysfunction in children and adults at risk of atherosclerosis[J].Lancet, 1992, 340:1111-1115.
[16]Anderson TJ, Vehata A, Gerhard MD, et al. Close relation of endothelial function in the human coronary and peripheral circulation[J]. J Am Coll Cardiol, 1995,26: 1235-1241.
[17]Corretti MC,Anderson TJ,Benjamin EJ,et al.Guidelines for the ultra-sound assessment of endothelial-dependent flow-mediated vasodilation ofthe brachial artery:a report of the International Brachial Artery Reac-tivity Task Force[J].J Am Coll Cardiol, 2002,39(2):257-265.
[18]杨欣,任卫东,杨军,等.应用心肌声学造影评价动脉粥样硬化心肌微血管内皮功能的实验研究[J].中国超声医学杂志,2006,22(09):650~652.
[19]黄晓波,刘伊丽,查道刚.静脉心肌声学造影早期检测冠脉微血管内皮功能障碍的实验研究[J].中国超声医学杂志, 2002, 18(5):321~323.
[20]Kjaer A,Meyer C,Nielsen FS,et al.Dipyridamole,cold pressor test,and demonstration of endothelial dysfunction:a PETstudy ofmyocardialperfusion in diabetes[J].J Nucl Med,2003,44(1):19-23.
[21]Celemajer DS. Endothelial dysfunction: Do itmatter? Is it reversible ? [ J] .J Am Coll Cardio,l 1997,30: 325-333.
[22]Laws PE,Spark JI,Cowled PA.The role of statins in vascular disease[J].Eur Jvasc Endovsc Surg,2004,279(1):6-16.
[23]刘伟,潘茗.不同剂量他汀类药物对冠心病并发高脂血症患者的血脂及血管内皮功能的影响,华北煤炭医学院学报,2008, 10(6):747-748.
[24]Mukai Y,Shimokawa H,Higashi M,et al.Inhibination of rennin-an- giotensin system ameliorates endothelial dysfunction with aging in rats [J].Arterisoscler Thromb Vasc Biol,2002,22(9):1 445-1 450.
[25]Newby DE.The rennin angiotensin system and endothelial dysfunction in chronic heart failure:role of endogenous fibrinolysis[J]. CongestHeart Fail,1999,5(6):254-259.
[26]Perticone F, Ceravolo R, Maio R,et al.Calcium antagonist isradipine improves abnormal endothelium-dependent vasodilation in never treated hypertensive patients [J]. Cardio Vasc Res, 1999, 41(1): 299-306.
[27]Miura S, FujinoM,Matsuo Y, et a.l Nifedipine-induced vascular endothelial growth factor secretion from coronary smoothmuscle cells promotes endothelialtuke forma- tion via the kinase insert domain-containing receptor/fetal liver kinase-1/NO pathway [J].HypertensRes, 2005, 28(2): 147-153.
[28]Farquharson CA,Butler R,Hill A,et al.Allopurinol improves endothelial dysfunction in chronic heart failure[J].Circulation,2002, 106(2):221-226.
[29]Rodriguez JA,Grau A,Eguinoa E,et al.Dietary supplementation with vitamins C and E prevents downregulation of endothelial NOS expression in hyperc-holesterolemia in vivo and in vitro[J].Atherosclerosis,2002,165(1):33-40.
[30]陈国雄,卜军,张存泰,等.卡维地洛对急性心肌梗死患者内皮功能及氧化指标的影响[J].临床心血管病杂志,2005,21(4):222-224.
[31]AiduPS,Singh A,Kulkarni SK.Carvedilol attenuates neuroleptic-in- duced orofacial dyskinesia:possible antioxidant mechanisms[J]. Br JPharmacol, 2002,136(2):193-200.
[32]GORNIK H L, CREAGER M A. Arginine and endothelial and vascular health[J]. J Nutr, 2004, 134:2880-2887.
[33]GEORGE J, SHMUEL S B, ROTH A. L-arginine attenuates lymphocyte activation and anti-oxidized LDL antibody levels in patients undergoing angioplasty[J]. Atherosclerosis, 2004,174:323-327.
[34]沈伟,白永怿,张象贤,等.L -精氨酸对肱动脉内皮功能的改善作用[J].临床心血管病杂志2006,22(11):653-655.
[2]杨功焕.健康模式转变与中国慢性病控制策略.中国慢性病预防与控制[J],2001, 9(4)145.
[3] Jean-Pierre Bassand.氯吡格雷治疗急性冠状动脉综合症:新证据和用药原则[S].中国医学论坛报, 2005, 6(30):18-19.
[4]吴海磊,张金良.气温及太阳活动变化对疾病发生的研究进展[J].卫生研究,2004,33(5):641-643.
[5]郭蕾,乔之龙.论开展六淫现代研究的重要意义[J].辽宁中医杂志,2004,31(7): 548-549.
[6]王锡稳,王宝鉴,黄玉霞,等.兰州市心血管病与气象条件分析[J].甘肃气象,2001, 19(1):29-32.
[7]李健,丁邦晗,张敏州等.胸痹心痛的临床证型与部分冠心病危险因素的对比研究[J].中西医结合心脑血管病杂志,2005,3(2):97-99.
[8]解玉水,吴士尧,王芝兰等.沪、疆两地急性心肌梗死的对比分析[J].中国综合临床,2005,21(9):786-788.
[9]成孚民,沈宝藩.成孚民医案医话集[M],新疆人民出版社,1985.
[10]安冬青,胡金霞,赵明芬,等.天香丹对冠心病病人血管内皮生长因子及相关因子的影响[J].中西医结合心脑血管病杂志,2007,5(8):662～664.
[11]安冬青,胡金霞,郑静,等.天香丹对冠心病患者血管新生相关因子的影响[J].新疆医科大学学报,2007,30(5):437～439.
[12]安冬青,施建民,姚海洪.天香丹对冠心病血管调节肽、血栓素A2/前列环素影响的临床与实验研究[J].心功能杂志,1998,10(2):118.
[13]安冬青.天香丹对冠心病患者血浆内皮素、降钙素基因相关肽的影响.中国医学文摘内科学分册英文版,1999,16(6):44.
[14]张玲,安冬青.天香丹颗粒对不稳定性心绞痛的相关炎性因子的影响[J].新疆中医药,2005,23(3):22～23.
[15]殷建明,朱江丽,刘琴,等.天香丹颗粒对冠心病心绞痛患者血清中T-SOD、GSH-Px、MDA、LD的影响[J].中国中医药信息杂志,2003,10(7):13～15.
[16]Michael A. Vascular endothelium:An integrator of pathophysio-logic stimuli theroscerosis[J]. Am J Cardiol,1995, 75:67B.
[17]潘雪峰,董华进,宫泽辉.内皮素与心血管功能研究的最新进展.国外医学(药学分册) ,2007,(01) :12-16.
[18]Conway EM,Van de Wouwer M,Pollefeyt S,et al.The lectin-like domain of thrombomodulin confers by suppressing adhesion activated protein kinase pathways.J ExPMed, 2002, 196 (5):565-577.
[19]LiYH,Chen JH,WuHL.et al.G-33A mutation in the promoter region of thrombomodulin geneand its assoeiation with coronary artery disease and plasma soluble thrombomodulin levels.AnlJCardio,2000,85(1):8-12.
[20]周仲英.中医内科学[M].第二版.北京中国中医药出版社. 2007,135-144.
[21]杨树勤.卫生统计学[M].第三版.北京:人民卫生出版社.1992.146.
[22]胡冬裴,胸痹证治文献研究[J],山东中医药大学学报,2005,9(1):38-40.
[23]梁达樵.辨证求真[M].广州十八甫维新印务局:光绪乙已,18-19.
[24]陈其昌.湿证发微[M].河南商务印刷所,民国十二年,25-30.
[25]殷建明,安冬青,通补开泄法治疗冠心病理论探讨[J].中医研究,2003,16(4):6-8.
[26]安冬青.天香丹耐缺氧及抗心肌缺血作用的试验研究[J].中国老医学杂志,2002,22: 47-48.
[27]张焱,安冬青.天香丹治气虚血瘀冠心病临床观察[J].江西中医药,2002,33(3):6-7.
[28]殷建明,朱江丽,安冬青.天香丹颗粒对冠心病心绞痛患者血清中T-SOD、GSH-PX、MDA、LD的影响[J].中国中医药信息杂志,2003,10(7):13-15.
[29]李必旭,安冬青,张焱.天香丹对冠脉结扎大鼠血浆NO、ET的影响[J].中医药研究,2002,18(1):41-42.
[30]安冬青,施建民,姚海洪.天香丹对冠心病血管调节肽、血栓素A2/前列环素影响的临床与实验研究[J].心功能杂志,1998,10(2):118.
[31]安冬青.天香丹对冠心病患者血浆内皮素、降钙素基因相关肽的影响[J].中国医学文摘内科学分册英文版,1999,16(3):44.
[32]杨建梅,安冬青.ICAM-1、VCAM-1与冠心病研究进展[J].新疆医学,2002,32(5):81.
[33]施建明,安冬青,张晓天等.天香丹治疗脂质代谢紊乱的临床研究[J].中国中医药信息杂志,1999,6(11):38-39.
[34]张玲,安冬青.天香丹颗粒对不稳定性心绞痛的相关炎性因子的影响[J].新疆中医药,2005,23(3):22-24.
[35]加力肯,安冬青.天香丹对冠心病稳定型心绞痛患者生活质量的影响及疗效分析[J].新疆医科大学学报,2006,29(11):1053-1055.
[36]Brown R E,Nahser P J, Rossen J D, et a.l Vasoconstriction of coro nary stenses from exposure to envionmental tobacoo smoke(abstract) [J]. JAm CollCardio,l 1994,(Suppl): 107A.
[37]KlasM, PeterB,Ander H. Clinical and biochemical factors associ ated with prognosis after myocardical infarction at a young age[J]. JAm CollCardiol,1994, 24: 59.
[38]周铭心.西北燥证研究概述[J].上海中医药杂志,2005,39(11):43-44.
[39]周铭心,凌泽奎.燥邪属性辨析—西北燥证病因学研究[J].新疆中医药.2005,23(6): 1-3.
[40]李超,安冬青,王娟,等.冠心病秽浊痰阻证与血浆同型半胱氨酸的相关性研究[J].中西医结合心脑血管病杂志,2008,6(4):384～385.
[41]孙红艳,安冬青,宋刚.冠心病秽浊痰阻证与血浆t-PA、PAI-1及Fib的相关性研究[J].中西医结合心脑血管病杂志,2009,7(4):389～390.
[42]王娟,安冬青,申艳慧,等.冠心病秽浊痰阻证与纤维蛋白原的关系探讨[J].中西医结合心脑血管病杂志,2008,6(4):383.
[43]王云龙,安冬青,朱萌,等.冠心病秽浊痰阻证与血管血友病因子的相关性研究[J].中西医结合心脑血管病杂志, 009,7(4):393～394.
[44]Rubanyi GM. The role of endothelium in cardiovascular homeostasis and diseases [J]. J Cardiovasc Pharmacol,1993, 22(Suppl 4): S1-S14.
[45]Paterick TE, Fletcher GF. Endothelial function and cardio-vascular prevention: role of blood lipids, exercise, and other risk factors[J]. Cardiol Rev, 2001, 9(5): 282-286.
[46]边东哲.动脉粥样硬化、冠心病与血管内皮细胞损伤机制的研究概况[J].湖南中医药导报,2003,(06) :63-65.
[47]Boehme M W, Raeth U, Scherbaum W A, et al. Interaction of endothelial cells and neutrophils in vitro: kinetics of thrombomodulin, intercellular adhesion molecule-1 (ICAM-1), E-selectin, and vascular celadhesion molecule-1 (VCAM-1): implications for the relevance as serological disease activity markers in vasculitides[J].Clin Exp Immunol,2000, 119:250.
[48]廖新学,李欣,马虹,等.冠心病患者血浆血栓调节蛋白水平的测定及其临床意义中国心血管杂志2003,8,(2)103-104.
[49]Lusis AJ.Atherosclerosis[J].Nature,2000,407(6 801):233-241.
[50]俞梦越,吴维力.内皮功能不全与冠心病[J].心血管病学进展,2002, (4):193-199.
[51]齐法莲,许军.内皮素研究与血管疾病[J].放射免疫学杂志,2002,15(4):246.
[52]Masaki T,Ninomiy H,Sakamoto A,et al.Structural basis of the function of endothelin eceptor[J].Mol Cell Biochem,1999,190:153-158.
[53]詹萍,熊尚全,郭跃进,等.不稳定性心绞痛不同中医证型与内皮素和心钠素关系[J].中西医结合心脑血管病杂志,2007,5(10):936-937.
[54]ZuK-Popiolek L,Flak Z,FrancuzT,et al.Plasma endothelin-1inpatients with stable or unstableangina[J].Kardiol Pol,2003,58(6):429-437.
[55]Herrmann J,Best PJ,Ritman EL,et al.Chronic endothelin receptor antagonism prevents coronary vasa vasorum neovascular-ization in experimental hypercholesterolemia [J]. J Ma Coll Cardiol,2002,39 (9):1555.
[56]李福刚,吾柏铭.冠心病患者血小板活化状态的观察[J].中华内科杂志,1993,32(1): 17-18.
[57]卢建敏,王丽霞,高思民.不稳定性心绞痛病人血浆内皮素的改变及低分子量肝素对它的影响[J].国外医学:心血管疾病分册,2000,27(2):100.
[58]郑春霞,刘志霞.血管内皮细胞损伤及其检测[J].肾脏病与透析肾移植杂志,2007,16 (1):64-65.
[59] Mombouli JV, Vanhoutte PM. Endothelial dysfunction:from physiology to therapy[J]. J Mol Cell Cardiol, 1999,31(1): 61-74.
[60]Kinlay S, Libby P, Ganz P. Endothelial function and coronary artery disease[J]. Curr Opi Lipidol, 2001,12 (4): 383-389.
[61]Farquharson CA,Butler R,Hill A,Belch JJ,StruthersAD.Allopurin improves endothelial dysfunction in chronic heart failure[J]. Circulation 2002,106(2):221.
[62]Hoeg JM. Expanding and understanding risk factors for coronary headisease[J]. JAMA, 1997,277(17):1387.
[63]中华医学会心血管病学分会中华心血管病杂志编辑委员会,第二届全国血脂异常学术研讨会会议纪要.中华心血管病杂志,2002,30:64 3-646.
[64]Gordon T, Kannel WB, Castelli WP, et al. Lipoproteins,cardiovascular disease,and death.The Framingham study. Arch Intern Med, 1981,141:1128-1131.
[65]冯宁.小、密低密度脂蛋白与冠心病[J].中华心血管病杂志,1997,25:237.
[66]Grundy SM.RoIe of low-density lipoproteins in atherogenesis and development of coronary heart disease. Clin Chem.1995 Jan;41(1):139-146.
[67]Rubins HB,Rubins SJ,Collins D,et al. Distribution of lidpids in 8500 men with coronary artery disease[J]. Am J Cardiol,1995,75:1196-1201
[68]Castelli WP,Garrision RJ,Wilson PW,et al. Incidence of coronary artery disease and lipoprotein cholesterol levels[J]. The Framing-ham study.JAMA,1986,256:2835-2838
[69]Stampter MJ,Krauss RM,Ma J, et a1.Aprospectiue study of triglyceride level,low-density lipoprotein particle diameter and risk of myocardial infraction.JAMA, l 996,276:882.
[70]韩学杰,沈绍功.中医治疗冠心病心绞痛研究进展[J].中国中医基础医学杂志,2003, 9(2):78-80.
[71]陈冰,宋剑南,牛小红,等.健脾祛痰化瘀方对氧化型低密度脂蛋白诱导血管细胞信号分子钙离子和蛋白激酶c表达的影响[J].中国动脉硬化杂志,2004,12(2):143-145.
[72]陈皋,宋剑南,史国锋,等.沥水调脂胶囊在体外对弱氧化型低密度脂蛋白诱导血管平滑肌细胞增殖的影响[J].中国中医基础医学杂志,2003,9(4):52-55.
[73]陈忠,黄峻.载脂蛋白E与动脉粥样硬化及早发冠心病[J].医学综述,2002,8(4):215- 216.
[74]蔡师敏,黄发盛.冠心病中医辨证分型与血脂关系分析[J].福建中医药,1993,30(6): 12.
[75]王剑,严灿,邓中炎,等.从粘附分子代谢失常探讨痰证机理[[J].中国中西医结合杂志,2000,20(4):296.
[76]张丽芬,李秀满.中医痰证的现代研究[J].天津中医学院学报,2000,12(3):17-19.
[77]宋剑南.中医药防治动脉粥样硬化研究进展[J].中国中医基础医学杂志,2003,9(11): 71-74.
[78]韩学杰.沈绍功教授从痰论治冠心病经验[J].中国中医急症,2004,13(1):31～32.
[79]谢海波,陈新宇,石刚,等.冠心病心绞痛中医证型与C-反应蛋白、血脂的相关性研究[J].湖南中医药大学学报,2005,25(4):32-34.
[80]于顾然,贺燕群,郭云庚,等.冠心病中医证型与胰岛素抵抗、脂质及红细胞膜酶关系的临床研究[J].中医杂志,2004,41(2):111-112.
[81]刘文波,殷少华,孙小键,等.冠心病患者血清尿酸和胆红素水平的变化[J].中华心血管病杂志, 2003, 31, (6): 439.
[82]Puddu PE,Lanti M,Menotti A,et al.Serum uric for short-term prediction of cardiovascular disease incidence in the Gubbio popu-lation study[J].Acta Cardiol,2001,56(4):243-251.
[83]Freedam DS,Williamson DF,Gunter EW,et al.Relation of serum uric acid to mortality and ischemic heart disease[J]. Am J Epidemiol, 1995, 141 (7):637-644.
[84]SattarN,Petrie JR,JaapAJ,et al.The atherogenic lipoprotein phenol type and vascular endothelial dysfunction[J].Atherosclerosis,1998,138:229-235.
[85]CerielloA.TabogaC.Tonutti L.Evidence for an independent and cumulative effect of postprandial hypertriglyceridemia and hyperglycemia on endothelial dysfunction and oxidative stressgeneration:effects of short and long-term simvastatin treatment[J]. Circulation,2002,106(10):1211-1218.
[86]Ward HJ.Uric acid as independent risk factor in the treat-ment of hypertension [J].Lancet,1998,352:670-671.
[87]Kanellis J,Watanabe S,Li JH,et al.Uric acid stimulates monocyte chemoattractant protein-1 production in vascular smooth muscle cells via mitogen-activated protein kinase and cyclooxygenase-2. Hypertension,2003,41:1287-1293.
[1]丁书文,李晓.冠心病内皮损伤防治研究进展[J].菏泽医专学报,2000,12,(3)180-182.
[2]边东哲.动脉粥样硬化、冠心病与血管内皮细胞损伤机制的研究概况[J].湖南中医药导报,2003,(06) .63-65.
[3]刘国英,陈还珍,吴博威.改善血管内皮功能防治冠心病研究进展[J].心血管病学进展,2006,27:39-41.
[4] Puranik R,Celermajer DS.Smoking and endothelial function[J].Prog Cardiovasc Dis,2003,45(6):443-584.
[5] Ali-Raza J,Movahed A.Current concepts of cardiovascular diseases in diabetes mellitus[J].Int J Cardiol,2003,89(2-3):123-134.
[6] Woodman CR,Price EM,Laughlin MH.Selected contribution:aging impairs nitric oxide and prostacyclin-mediation of endothelium-dependent dilation in soleus feed arteries[J].J Appl Physiol,2003,95(5):2164-2170.
[7] Shah SV,Alam MG.Role of iron in atherosclerosis[J].Am J Kidney Dis,2003,41(3 suppl 1):S80-S83.
[8] Nedeljkovic ZS,Gokce N,Loscalzo J.Mechanisms of oxidativestress and vascular dysfunction[J].Postgrad Med J,2003,79:195-200.
[9]廖新学,李欣,马虹,等.冠心病患者血浆血栓调节蛋白水平的测定及其临床意义[J]中国心血管杂志,2003,8 (2):103-104.
[10]Lusis AJ.Atherosclerosis[J].Nature,2000,407(6 801):233-241.
[11]俞梦越,吴维力.内皮功能不全与冠心病[J].心血管病学进展, 2002, (04):193-199.
[12]Vanhoutte PM.Endothelial dysfunction and atherosclerosis[J].Eur heart J,1997,18(suppl):19-29.
[13]Makin AJ,Blann AD,ChungNA,et al.Assessment of endothelial damage in atheroscler- otic vascular disease by quantification of circulatingendothelial cells.Relationship with von Willebrand factor and tissuefactor[J].Eur Heart J,2004,25(5):371-376.
[14]Tio RA,Monnink SH,Amoroso G,et al.Safety evaluation of routine in-tracoronary acetylcholine infusion in patients undergoing a first diagnos-tic coronary angiogram[J].J InvestigMed,2002,50(2):133-139.
[15]Celermajer DS, Sorensen KE, Gooch VM, et al. Non-invasive detection of endothelial dysfunction in children and adults at risk of atherosclerosis[J].Lancet, 1992, 340:1111-1115.
[16]Anderson TJ, Vehata A, Gerhard MD, et al. Close relation of endothelial function in the human coronary and peripheral circulation[J]. J Am Coll Cardiol, 1995,26: 1235-1241.
[17]Corretti MC,Anderson TJ,Benjamin EJ,et al.Guidelines for the ultra-sound assessment of endothelial-dependent flow-mediated vasodilation ofthe brachial artery:a report of the International Brachial Artery Reac-tivity Task Force[J].J Am Coll Cardiol, 2002,39(2):257-265.
[18]杨欣,任卫东,杨军,等.应用心肌声学造影评价动脉粥样硬化心肌微血管内皮功能的实验研究[J].中国超声医学杂志,2006,22(09):650~652.
[19]黄晓波,刘伊丽,查道刚.静脉心肌声学造影早期检测冠脉微血管内皮功能障碍的实验研究[J].中国超声医学杂志, 2002, 18(5):321~323.
[20]Kjaer A,Meyer C,Nielsen FS,et al.Dipyridamole,cold pressor test,and demonstration of endothelial dysfunction:a PETstudy ofmyocardialperfusion in diabetes[J].J Nucl Med,2003,44(1):19-23.
[21]Celemajer DS. Endothelial dysfunction: Do itmatter? Is it reversible ? [ J] .J Am Coll Cardio,l 1997,30: 325-333.
[22]Laws PE,Spark JI,Cowled PA.The role of statins in vascular disease[J].Eur Jvasc Endovsc Surg,2004,279(1):6-16.
[23]刘伟,潘茗.不同剂量他汀类药物对冠心病并发高脂血症患者的血脂及血管内皮功能的影响,华北煤炭医学院学报,2008, 10(6):747-748.
[24]Mukai Y,Shimokawa H,Higashi M,et al.Inhibination of rennin-an- giotensin system ameliorates endothelial dysfunction with aging in rats [J].Arterisoscler Thromb Vasc Biol,2002,22(9):1 445-1 450.
[25]Newby DE.The rennin angiotensin system and endothelial dysfunction in chronic heart failure:role of endogenous fibrinolysis[J]. CongestHeart Fail,1999,5(6):254-259.
[26]Perticone F, Ceravolo R, Maio R,et al.Calcium antagonist isradipine improves abnormal endothelium-dependent vasodilation in never treated hypertensive patients [J]. Cardio Vasc Res, 1999, 41(1): 299-306.
[27]Miura S, FujinoM,Matsuo Y, et a.l Nifedipine-induced vascular endothelial growth factor secretion from coronary smoothmuscle cells promotes endothelialtuke forma- tion via the kinase insert domain-containing receptor/fetal liver kinase-1/NO pathway [J].HypertensRes, 2005, 28(2): 147-153.
[28]Farquharson CA,Butler R,Hill A,et al.Allopurinol improves endothelial dysfunction in chronic heart failure[J].Circulation,2002, 106(2):221-226.
[29]Rodriguez JA,Grau A,Eguinoa E,et al.Dietary supplementation with vitamins C and E prevents downregulation of endothelial NOS expression in hyperc-holesterolemia in vivo and in vitro[J].Atherosclerosis,2002,165(1):33-40.
[30]陈国雄,卜军,张存泰,等.卡维地洛对急性心肌梗死患者内皮功能及氧化指标的影响[J].临床心血管病杂志,2005,21(4):222-224.
[31]AiduPS,Singh A,Kulkarni SK.Carvedilol attenuates neuroleptic-in- duced orofacial dyskinesia:possible antioxidant mechanisms[J]. Br JPharmacol, 2002,136(2):193-200.
[32]GORNIK H L, CREAGER M A. Arginine and endothelial and vascular health[J]. J Nutr, 2004, 134:2880-2887.
[33]GEORGE J, SHMUEL S B, ROTH A. L-arginine attenuates lymphocyte activation and anti-oxidized LDL antibody levels in patients undergoing angioplasty[J]. Atherosclerosis, 2004,174:323-327.
[34]沈伟,白永怿,张象贤,等.L -精氨酸对肱动脉内皮功能的改善作用[J].临床心血管病杂志2006,22(11):653-655.